ADvantage Therapeutics Welcomes Dr. William Haseltine as Strategic Advisor to Drive Innovation
ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a major focus on Alzheimer’s Disease (AD). We are currently preparing for clinical trials in Europe and in the US. Furthermore, ADvantage is developing potentially paradigm-changing therapies to treat AD in its labs at the Vienna BioCenter.
MORE ABOUT US Our BreakthroughThe most fruitful basis of the discovery of a new
drug is to start with an old drug.
~ Sir James W. Black,
1988 Nobel Prize in Medicine
We will sustain a knowledge-building culture, rooted in win-win relationships, that combines leading-edge scientific skill, unencumbered by conventional assumptions, with a passion for bringing paradigm-changing medical treatments to patients worldwide.
Jeffrey Madden
Since we have found by serendipity the first disease-modifying compound for Alzheimer’s, we will make Alzheimer’s patients to benefit at last!
Walter Schmidt
Developing a novel Alzheimer’s drug with disease modifying potential together with global investigators and employing state-of-the-art clinical tools is in and of itself inspiring.
Achim Schneeberger
Over the last 20 years, Alzheimer’s research concentrated on therapies to produce antibodies against different amyloid-beta peptide species, which were shown to accumulate in the brains of Alzheimer’s patients. However, clinical trial efficacy proved elusive.
Meanwhile, the research team led by Drs. Frank Mattner, Walter Schmidt and Achim Schneeberger developed a (mimotope-based) vaccine, AD02, against amyloid-beta peptides (with a free N-terminus).
In 2014, the team orchestrated a double-blinded, randomized clinical phase 2 trial with AD02 in 332 Alzheimer’s patients. In this trial, Alhydrogel® (now called AD04™) served as a control group.
Unexpectedly, the patients from the control group significantly benefited from the AD04™ application while the AD02 vaccinated groups did not. The shrinkage of the Hippocampus, where memory and orientation are located, was positively impacted by AD04™ treatment coupled with slowdown of cognitive decline.
After several years of negotiation, Frank and Walter bought the patent rights for AD04™. They joined Agustin Fernandez and Jeffrey Madden and founded ADvantage Therapeutics Inc. in order to provide Alzheimer’s patients a transformative, life-enhancing treatment.
*1 The Hippocampus is the part of the brain that harbors memory and orientation functions.
Our product candidate, AD04™, is a known immuno-stimulant: this compound has been widely used as an adjuvant in human and animal vaccination programs and has a well-established safety record. However, injection of this compound as single ingredient for the treatment of AD is a proprietary approach.
What results have you seen that support the clinical development of AD04™?
Our data obtained in patients with early AD indicated that AD04™, applied repeatedly to the subcutis of the upper arm induced a statistically significant slower decline over the combined 4 other groups on clinical outcomes (e.g. cognition and quality of life) and MRI hippocampal volume as biomarker. Importantly, reduced loss of the hippocampal volume correlated with significantly less decline in cognitive measures, e.g., adapted Alzheimer’s Disease Assessment Scale-cognitive (aADAS-cog), but not in functional endpoints supporting AD04™ as a therapeutic entity (see “Summary of Phase 2”).
AD04™ tested in the respective clinical trial arm (n=51 patients) was safe and well tolerated. There was neither evidence for autoimmunity nor for hematological abnormalities or hepato-/nephrotoxicity.
MORE ABOUT OUR SCIENCE Our PipelineThe world desperately needs disease-modifying therapies for AD: we combine immunology and neuroscience to create first-in-class therapeutics.
MORE ABOUT OUR PIPELINEAAIC24_Poster_template v5
Disease modifying therapies (DMTs) are a focus of research for Alzheimer’s disease (AD). DMTs are expected to change the trajectory of disease progression and slow...
Dr. Kuro-o to speak at Second Annual Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton, Florida BOCA RATON, FL and Vienna, Austria, February...
MIAMI, November 27, 2023 (GLOBE NEWSWIRE) – ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions by addressing the biology...
ADvantage also acquires intellectual property to enhance its Alzheimer’s disease and longevity portfolios
Jeffrey Madden speaks with Dave, The CareGiver's Caregiver to discuss all things Alzheimer's including breakthroughs in research; immunotherapy; pathophysiology; combining with other medications; clinical trial...
MIAMI, June 20, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions with a focus on Alzheimer’s disease, today announced that regulatory authorities in Poland, Bulgaria, and Slovakia have approved its Clinical Trial Application
We are excited about the recent MHRA announcement regarding new regulatory recognition pathways that will facilitate the introduction of innovative drugs to the UK by leveraging other countries' drug registrations.
Our work suggests that our lead therapeutic (AD04™) regulates the immune system to provide patients with a unique positive effect on the course of Alzheimer’s Disease pathology. Our vision is to provide patients with a disease-modifying therapeutic for early Alzheimer’s Disease, thereby making the world a distinctly better place.
All decisions are made with the best interest of the patient. Period.
Root-cause explanations — with experimental evidence — drive our work and may overturn widely held assumptions. Knowledge building is in our DNA.
Integrity is key. We seek win-win relationships with stakeholders inside and outside the organization. We are only as good as our word.
Entrepreneurs at heart, we thrive taking on significant challenges and breaking new ground. In the words of Marie Curie, “I was taught that the way of progress was neither swift nor easy.”
Vaccines using Alhydrogel® (e.g. AD02) contain in addition an antigen, which plays a central role in guiding the immune response. Thus, AD04™ as single ingredient stimulates necessarily the immune system in a different way.
AD04™ tested in preclinical studies improved cognition, mirroring the results of the clinical trial. Nevertheless, the mode of action of AD04™ on Alzheimer’s brain is not fully understood. Our hypothesis is that AD04™ regulates the immune system in a way that reduces AD pathology. To test this assumption, we are conducting additional preclinical studies in parallel to clinical development. We aim to demonstrate how AD04™ regulates cellular/molecular processes associated to neuroinflammation and neurodegeneration. For that purpose, we use state-of-the-art multi-omics, biochemistry, and immunohistology techniques.
Concomitantly to defining the mode of action of AD04™, the preclinical studies aim to identify pharmacodynamic biomarkers easily accessible (e.g. in the blood) that will then be tested in the clinical trial. Such biomolecules, so-called surrogate markers of clinical outcome, are important in clinical trials to measure more accurately pathway and/or target engagement (enabling dose selection), and to obtain faster data of the therapeutic impact of the tested compound (enabling decisions on the next phase of development).
We have observed that AD04™, an immuno-modulator, is effective in the clinic having an effect in the brain, particularly on the hippocampus, a part associated to memory; with this understanding, we have built a pipeline of discovery-stage compounds (see Table).
Our strategy focuses on deep learning from AD04™-triggered biological pathways to..
…harness specific circuits of the immune system to inhibit AD
…create therapeutics tackling specific biomolecules having specific function(s) along these pathways, e.g novel immuno-modulator of a neuro-inflammatory axis in the hippocampus
Thus, AD10 to AD13 are discovery-stage drugs that will be selected for their impact on relevant pharmacodynamic biomarkers identified in the AD04™ preclinical program (see § “How are the preclinical studies of AD04™ informing the clinical development?”).
Lipids and lipid circuits play a crucial role in the pathogenesis of AD, reflecting the fact that the brain is an organ with high lipid content. We investigate compounds potentially able to restore lipid homeostasis in the brain.
Using an appropriate panel of pharmacodynamics biomarkers that will be identified in the AD04™ preclinical program, we plan to setup an investigational blood-based diagnostic assay for AD.
We design optimized mRNAs encoding relevant proteins as investigational therapeutics (e.g. AD09) for treating AD.
Typically, our program starts with 5 to 10 mRNA candidates encoding the protein of interest designed by our platform (level A). These are screened for efficacy and compared to the native sequence in relevant in vitro assays (level B). The next step is the in vivo validation of the results obtained in vitro (level C). Further analysis steps might be necessary depending of the protein.
Key features of our mRNA platform:
Jeffrey Madden is a Co-founder and Chief Executive Officer at ADvantage Therapeutics. His career spans more than 20 years in the institutional investment management industry including Partner and Portfolio Manager at IronBridge Capital Management and Senior Vice President and Portfolio Manager at RMB Capital. He also worked at Accenture in the Management Consulting Practice. Jeffrey is an active board member and lead investor of Rational Vaccines, which is developing therapeutic and prophylactic live attenuated vaccines for HSV-1 and HSV-2. He also serves on the boards of Leading India’s Future Today, which offers educational programs attuned to sound economic thinking, and the Bartley J. Madden Foundation, which creates employment opportunities for those most in need. Jeffrey graduated from the University of Iowa with Business Honors and Distinction.
David Buchsbaum is the Chief Financial Officer at ADvantage Therapeutics. He is also currently Managing Director at a boutique Investment Bank specializing in healthcare and biotechnology. After starting at Claire’s Stores, a NYSE fashion accessories retailer, he spent most of his career as a senior equity analyst where he covered consumer discretionary companies most notably at Wells Fargo. More recently Mr. Buchsbaum helped manage the Holtzman Opportunity Fund, a shareholder activist hedge fund and private equity holdings for Jewelcor. He has a J.D. in Law from the University of Miami and a B.S. in business from the University of Richmond.
Mr. Jarry combines a business background (12 years with Accenture) with 25 years of life sciences experience including Novartis, Bayer, Bristol-Myers Squibb and midsize biopharma. His responsibilities covered Strategy, M&A, regional leadership and finance-associated roles. He has had financial responsibility for sales in excess of $1.4 billion and M&A in excess of $1.1 billion. He has negotiated and managed agreements with nine-digit annual value in North and Latin America, Western and Eastern Europe, China and Japan. Mr. Jarry’s experience in vaccines includes addressing the H1N1 pandemic flu of 2009 with authorities in Europe and ex USSR.
Dr. Achim Schneeberger has over 20 years’ experience in biomedical research and development focusing on immunotherapeutic approaches in cancer and chronic diseases. Following the study of Medicine at the Universities of Tübingen, Germany and Bordeaux, France, he started his career at the Department of Dermatology, Medical University of Vienna, Austria. At the time, he studied melanoma vaccines and was instrumental in translating the most promising candidates into the arena of clinical testing. This work and its results led to several prizes including the thesis award of the Medical University of Tübingen and the Egner Dermatooncology Prize of the German Dermatological Research Society. In 2005, Dr. Schneeberger joined the Laboratory of Prof. Yokoyama at Washington University, Saint Louis, to study the interactions between NK cells and cancer. Upon returning to Europe, he joined AFFiRiS to build and lead their clinical department. As CMO, he was responsible for the clinical development of the company’s vaccine candidates. Under his lead, AFFiRiS initiated clinical programs in the indications of Alzheimer’s, Parkinson’s, MSA and atherosclerosis covering a total of 18 clinical trials. He was instrumental for AFFiRiS being awarded with significant grants from the Michael J. Fox Foundation and the European Union (FP7 programs SYMPATH and MultiSYN).
Dr. Walter Schmidt studied biology at the university of Göttingen, Germany. He got his PhD in 1990 at the Max-Plank-Institute of Experimental Medicine with Fritz Eckstein and was awarded the Otto-Hahn Medal for his thesis. From 1991 till 1997 he started as Postdoc and later became staff scientist at Boehringer’s “think tank” Institute of Molecular Pathology in Vienna, Austria. Walter co-founded Intercell (now Valneva) in 1991, the first Austrian biotech company that went public serving as CTO in the beginning and Founding Vice President for Business Development afterwards. Later in 2003, he co-founded together with Dr. Frank Mattner, AFFIRIS and served as CEO until he moved on to co-found ACCANIS in 2015 again together with Dr. Mattner. 2021 he became a co-founder of ADvantage Inc. and since then he is member of the Board of Directors and Director of the mRNA department.
Carmela R. Abraham, Ph.D., devoted her entire career to the study of aging and Alzheimer’s disease (AD). She obtained her B.Sc. in Biology at Tel Aviv University and a Ph.D. in Neuroscience at Harvard University. She is Professor Emerita of Biochemistry and Pharmacology & Experimental Therapeutics at Boston University School of Medicine. Dr. Abraham’s research is both basic and translational. The basic research focuses on understanding the pathologic mechanisms leading to AD and to other neurodegenerative diseases. Dr. Abraham studies ways to protect the nerve cells that die in these diseases and, thus, prevent brain dysfunction. Her group discovered that the Klotho protein, whose levels decrease with age, is neuroprotective, anti-oxidative and anti-inflammatory. In mouse models of AD, multiple sclerosis and ALS, increasing the levels of Klotho improved the outcomes of these diseases. Since higher Klotho levels are associated with better outcomes, Dr. Abraham is exploring various modalities to elevate the Klotho protein. Based on her findings of 43 years of studying normal aging and AD, she is now focused on finding drugs that would either prevent or alleviate the symptoms of AD and other age-related diseases, such as cancer and kidney disease. She is a co-founder of Klogenix (formerly Klogene), a biotech startup with the same mission; the company was the recipient of a $1.5M NIH grant to advance this research. Dr. Abraham was the first Rappaport fellow at the Center for Neurologic diseases at Brigham and Women’s Hospital, and the recipient of the Zenith and Temple awards from the Alzheimer’s Association. Carmela has directed and taught a course entitled Molecular Basis of Neurologic Diseases for over 25 years, and has mentored numerous undergraduate and graduate students and postdoctoral fellows. Her research has been supported by the NIH, Alzheimer’s Association, Boston University Ignition Award, the Massachusetts Neuroscience Consortium Award, the Cure AD Fund and Alzheimer’s Drug Discovery Foundation.
Dr. Thomas Hoffmann pursued his academic journey in molecular biology at the esteemed University of Vienna. Upon the successful completion of his diploma thesis at the Ludwig Boltzmann Institute for Cancer Research (LBICR), he went on to achieve his Ph.D. with distinction at the Research Institute of Molecular Pathology (IMP) in 2015. During his tenure under the mentorship of Prof. Johannes Zuber, he focused on advancing RNA interference tools within the field of hematology. Following a brief postdoctoral stint within the same laboratory, Dr. Hoffmann assumed the role of Laboratory Scientist at Accanis, where he spearheaded the development and implementation of protocols for assessing mRNA treatments in both human (ex vivo) and porcine (in vivo and ex vivo) skin. In November 2021, Thomas transitioned to the mRNA department at ADvantage Therapeutics, dedicating his efforts to fortifying the company's mRNA intellectual property (IP) position across various domains. Dr. Thomas Hoffmann's contributions extend beyond his research, as evidenced by his co-authorship of over 25 scientific papers and his status as the holder of multiple patents.
Dr. Makoto Kuro-o, M.D., Ph.D., is a professor at the Center for Molecular Medicine, Jichi Medical University, Japan. He received his degrees from the University of Tokyo, Japan. Dr. Kuro-o has over 30 years of research and clinical experience in endocrinology, endocrine FGF, molecular biology of aging, nephrology and mineral metabolism. He discovered and named the Klotho gene and since then, over the last 24 years, has published extensively on it. Dr. Kuro-o’s pioneering research opened up a new and very promising path toward understanding longevity as well as preventing and treating diseases.
Dr. Lemere is a Scientist in the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital and Associate Professor of Neurology at Harvard Medical School in Boston, MA USA. Her research focuses on understanding and using the immune system therapeutically to prevent and treat Alzheimer's disease. Dr. Lemere earned a bachelor’s degree in psychology and education from Mount Holyoke College and a master’s in neurobiology from SUNY Albany. Her current research involves: 1. nonclinical studies of antibody treatments targeting a pathogenic form of amyloid-beta protein found in plaques in Alzheimer’s disease brain; 2. the role of the innate immune system’s complement signaling in aging and Alzheimer’s disease; and 3. the effects of deep space galactic cosmic radiation on brain aging and the risk of Alzheimer’s disease in studies in mouse models and human neural cells in preparation for NASA’s first manned mission to Mars. Her lab is funded by NIH and NASA. Dr. Lemere serves as an advisor to the Alzheimer’s Association, the BrightFocus Foundation and Cure Alzheimer’s Fund. In addition, she serves as a consultant for several companies.
Dr. Tanzi is the Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, Co-Director of the Henry and Allison McCance Center for Brain Health, and Co-Director of the MassGeneral Institute for Neurodegenerative Disease at Massachusetts General Hospital. He also serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. Dr. Tanzi received his B.S. (microbiology) and B.A. (history) at the University of Rochester in 1980 and his Ph.D. (neurobiology) at Harvard Medical School in 1990.
Dr. Tanzi was a key member of the teams that discovered the first Alzheimer’s disease (AD) gene, the amyloid precursor protein (APP) gene, and the two other early-onset familial AD genes, presenilin 1 and presenilin 2. As leader of the Cure Alzheimer’s Fund Alzheimer’s Genome Project, Dr. Tanzi identified several other AD genes, including CD33, the first AD gene shown to regulate neuroinflammation in AD. He also discovered the Wilson’s disease gene and several other neurological disease genes.
Dr. Tanzi’s team was the first to use human stem cells to create three-dimensional mini human brain organoids of AD, dubbed “Alzheimer’s-in-a-Dish”. This model was the first to recapitulate all three key AD pathological hallmarks. He and his team have successfully used these organoids to screen for approved drugs and natural products that can stop AD brain pathology. Dr. Tanzi has developed several novel therapies for AD including gamma secretase modulators targeting amyloid pathology (Phase 1 planned 2021) and AMX0035, which was already successful in a clinical trial of ALS and now under priority review for approval at the FDA. Dr. Tanzi also discovered that beta-amyloid plays a functional role in the brain as an anti-microbial peptide, supporting a potential role for infection in the etiology of AD.
Dr. Tanzi serves as Chair of the Cure Alzheimer’s Fund Research Leadership Group and on numerous scientific advisory and editorial boards, He has published over 600 research papers and is one of the top 50 most cited neuroscientists in the world. He has received the highest awards in his field, including the Metropolitan Life Foundation Award, Potamkin Prize, Ronald Reagan Award, Oneness in Humanity Award, Silver Innovator Award, the Smithsonian American Ingenuity Award, the Brain Research Foundation Award, and the Kary Mullis Award for Medical Research. He has also been named to TIME magazine’s list of TIME100 Most Influential People in the World. Dr. Tanzi is also a New York Times bestselling author, who has co-authored the books Decoding Darkness, and bestsellers, Super Brain, Super Genes, and The Healing Self.
Dr. Gauthier is a member of Departments of Neurology and Neurosurgery, Psychiatry and Medicine of McGill University. Director of Alzheimer Disease and Related Disorders Research Unit at the McGill Center for Studies in Aging, and Research Chair in the Canadian Institutes for Health Research program for health research. Many prizes and distinctions such as 2009 “Irma M. Parhad Award for Excellence”, 2012 “prix Hubert Reeves”, 2014 “Queen Elisabeth II Diamond Jubilee Medal” and member of the “Order of Canada”.
Professor of Neurology, Sorbonne University, Paris; Director of the Behavioural Neurology Department and of the Dementia Research Center at Salpêtrière Hospital, Paris; Director of a Research Unit Inserm at Paris Brain Institute. Past-President of the French Society of Neurology. Coordinator of the Center of Excellence in Neurodegeneration (CoEN) of Paris. Member of the ‘Académie Nationale de Médecine’. Many prizes and distinctions such as “Chevalier de la Legion d’Honneur”. Member of the European Alzheimer Disease Consortium (EADC) and of the European Academy of Neurology (EAN). Principal or co-investigator of a number of research programs focusing on Alzheimer’s disease and Parkinson disease. Chairman of the International Working Group (IWG) on the new criteria for Alzheimer’s disease.
Prof. Dr. med. Oliver Peters, Full Professor at Charité Universitätsmedizin Berlin, is currently chief of the branch Geriatric Neuropsychiatry at the Department of Psychiatry and Psychotherapy, Charité - Campus Benjamin Franklin. He is head of the Memory Clinic and Dementia Prevention Center at Experimental Clinical Research Center (ECRC), Charité - Campus Berlin Buch. He is principal investigator at the German Center for Neurodegenerative Diseases (DZNE) and board member of the German Dementia Competence Network (KND e.V.). He is interested in the establishment of, and has extensively worked on, new biomarkers for early diagnosis of chronic neurodegenerative diseases. He has participated as Principal Investigator in numerous observational and interventional clinical trials.
Please contact:
PRIM. DR. ANDREAS WINKLER, MSC
Specialist in Neurology and Geriatrics
General Practitioner
PRIVATORDINATION WIEN
MED-18
Theresiengasse 46/2
A-1180 Wien
+43 1 3990863
[email protected]
www.neurologie-winkler.at
PRIVATORDINATION KORNEUBURG
MED SPACE
Hauptplatz 18 / 2. OG / Top H04
A-2100 Korneuburg
+43 2262 73573
[email protected]
www.neurologie-winkler.at
Kontaktieren Sie bitte:
PRIM. DR. ANDREAS WINKLER, MSC
Facharzt für Neurologie und Geriatrie
Arzt für Allgemeinmedizin
PRIVATORDINATION WIEN
MED-18
Theresiengasse 46/2
A-1180 Wien
+43 1 3990863
[email protected]
www.neurologie-winkler.at
PRIVATORDINATION KORNEUBURG
MED SPACE
Hauptplatz 18 / 2. OG / Top H04
A-2100 Korneuburg
+43 2262 73573
[email protected]
www.neurologie-winkler.at
These Terms of Use (“Terms”) govern your use of our website at www.advantagetherapeutics.com as well as any other online services that ADvantage Therapeutics Inc. (“ADvantage Therapeutics,” “we,” or “us”) operates and that links to these Terms (collectively, the “Online Resources”).
Please review these Terms carefully before using the Online Resources. We may change these Terms or modify any features of the Online Resources at any time. The most current version of the Terms can be viewed by clicking on the “Terms of Use” link posted on the Online Resources. You accept the Terms by using the Online Resources, and you accept any changes to the Terms by continuing to use the Online Resources after we post the changes.
Our Online Resources are directed to a general audience and not to children. By accessing or using the Online Resources, you represent and warrant to us that you are at least 18 or the age of majority in your jurisdiction required to form a binding contract. If you are accessing or using the Online Resources on behalf of an entity, you represent and warrant that you have the authority to bind that entity to the Terms.
1. By using the Online Resources, you consent to our processing your information consistent with the ADvantage Therapeutics Website Privacy Policy.
2. Information and Educational Purposes. The Online Resources and the information we provide through the Online Resources is for general information and educational purposes only. For example, such information may include information relating to medical conditions and treatment of those conditions. That information is provided only for informational purposes and is not intended to be a substitute for advice provided by a doctor or other qualified healthcare professional. It should not be used for diagnosis or treatment of a health condition. For advice or information about diagnosis or treatment of a health condition, you should always consult with a competent, licensed doctor or other healthcare professional.
3. Content. We use reasonable efforts to ensure that the information we make available through the Online Resources is accurate, current, and complete. However, due to various factors, we make no representations or warranties of any kind (either express or implied) as to the quality, accuracy, completeness, timeliness, or currency of any such information. The ONLINE RESOURCES AND ANY INFORMATION ON THEM is provided to you “as is” for your use in accordance with these terms only. You agree that you must evaluate, and bear all risks associated with, your use of any such information. ADvantage Therapeutics (and all other parties involved in creating, producing, and delivering such information and the online resources) disclaim any and all liability in connection therewith. The Online Resources may contain information provided by third parties or may contain links to third-party websites, content, and services. We do not control, endorse, sponsor, recommend, or otherwise accept responsibility for the information provided by third parties, or the websites, content, or services of third parties to which we provide links. We expressly disclaim any liability for any errors or omissions in the content included in the Online Resources or any third party sites linked to or from the Online Resources.
4. Copyrights. The Online Resources contain copyrighted material and other proprietary information, and the entire content of the Online Resources is protected by United States copyright laws. You may not publish, reproduce, distribute, display, perform, edit, adapt, modify, or otherwise exploit any part of the Online Resources without our written consent. ADvantage Therapeutics makes no representations or warranties that your use of content available through the Online Resources will not infringe a third party’s rights.
5. Trademarks and other Proprietary Rights. ADvantage Therapeutics and other names, logos, designs, slogans, trademarks, service marks and trade dress on the Online Resources are owned by ADvantage Therapeutics or its affiliates or licensors, and may not be copied, imitated or used, in whole or in part, without prior written consent from ADvantage Therapeutics. No license to, or right in, any such proprietary rights of ADvantage Therapeutics or other parties is granted to, or conferred upon, you.
6. Prohibited Conduct. You many not access or use, or attempt to access or use, the Online Resources to take any action that could harm us or any third party, interfere with the operation of the Online Resources, or use the Online Resources in a manner that violates any laws. For example, and without limitation, you may not:
Violations of system or network security may result in civil or criminal liability. We may investigate and work with law enforcement authorities to prosecute visitors who violate the Terms. We may suspend or terminate your access to the Online Resources for any or no reason at any time without notice.
7. Indemnity. YOU AGREE TO INDEMNIFY, DEFEND, AND HOLD US AND OUR AFFILIATES, OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, REPRESENTATIVES, AND THIRD-PARTY PARTNERS (collectively, the “INDEMNIFIED PARTIES”) HARMLESS FROM AND AGAINST ANY AND ALL LOSS, COSTS, EXPENSES (INCLUDING REASONABLE ATTORNEYS’ FEES AND EXPENSES), CLAIMS, DAMAGES, AND LIABILITIES RELATED TO OR ASSOCIATED WITH YOUR USE OF THE ONLINE RESOURCES AND ANY ALLEGED VIOLATION BY YOU OF THESE TERMS. WE RESERVE THE RIGHT TO ASSUME THE EXCLUSIVE DEFENSE OF ANY CLAIM FOR WHICH WE ARE ENTITLED TO INDEMNIFICATION UNDER THIS SECTION. IN SUCH EVENT, YOU SHALL PROVIDE US WITH SUCH COOPERATION AS WE REASONABLY REQUEST.
8. Limitations of Liability. In no event will we OR ANY OF THE INDEMNIFIED PARTIES be liable For any direct or indirect, special, incidental, consequential or punitive damages, lost profits, or other damages whatsoever arising in connection with the use of the online resources, any interruption in availability of the online resources, delay in operation or transmission, computer virus, loss of data, or use, misuse, reliance, review, manipulation, or other utilization in any manner whatsoever of the online resources or the data collected through the online resources, even if one or more of them has been advised of the possibility of such damages or loss. ANY CLAIM ARISING OUT OF OR CONNECTED WITH THE ONLINE RESOURCES WILL BE LIMITED TO THE GREATER OF $50 OR THE AMOUNT YOU HAVE PAID US IN THE PAST TWELVE MONTHS.
9. Governing Law; Venue; Limitation of Claims. The Terms shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, USA without regard to its conflicts of laws principles. You hereby consent to exclusive jurisdiction and venue in the state and federal courts of Middlesex County, Commonwealth of Massachusetts, USA for resolution of any and all controversies, disputes, demands, counts, claims, or causes of action arising out of or relating to these Terms. You and ADvantage Therapeutics submit to the personal jurisdiction of such courts for those purposes. Any claim either party has against the other under these Terms must be brought within one (1) year after the cause of action arises.
10. General. The Terms constitute the entire agreement between you and us, superseding any prior or contemporaneous communications and proposals (whether oral, written, or electronic) between you and us. In the event any provision of these Terms is held unenforceable, it will not affect the validity or enforceability of the remaining provisions and will be replaced by an enforceable provision that comes closest to the intention underlying the unenforceable provision. You agree that no joint venture, partnership, employment, or agency relationship exists between you and us as a result of the Terms or your access to and use of the Online Resources.
Our failure to enforce any provisions of these Terms or respond to a violation by any party does not waive our right to subsequently enforce any terms or conditions of the Terms or respond to any violations. We reserve the right to assign our rights and obligations under the Terms. However, except with our prior written consent, you may not assign any of your rights or obligations under the Terms. All rights and remedies of ADvantage Therapeutics hereunder are cumulative and in addition to those at law and in equity. Nothing contained in these terms is in derogation of our right to comply with governmental, court, and law enforcement requests or requirements relating to your use of the Online Resources or information provided to or gathered by us with respect to such use.
11. Contacting Us. You may contact ADvantage Therapeutics at:
ADvantage Therapeutics Inc.
195 NW 40th Street
Miami, FL 33127
This Privacy Policy governs the manner in which ADvantage Therapeutics Inc. (“ADvantage Therapeutics,” “we,” or “us”) collects, uses, maintains and discloses information collected from visitors through our website at www.advantagetherapeutics.com as well as any other online services that we operate and that link to this Privacy Policy (collectively, the “Online Resources”).
By using the website or any of the Online Resources, you consent to our collection, use, and disclosure of your information consistent with this Privacy Policy.
We collect some information automatically when you use our Online Resources, such as your Internet Protocol (IP) address, browser and operating system type and version, Internet service provider, pages that you visit before and after using the Online Resources, the date and time of your visit, information about the links you click and pages you view within the Online Resources, and other standard server information.
We may also use cookies and similar technologies to automatically collect this information. Cookies are small bits of information that are stored by your computer’s web browser. By using the Online Resources, you consent to our use of cookies and similar technologies.
We use information to analyze and improve the Online Resources. We also use information to measure the number of visitors to our site and numbers of visitors to various sections of our site for the purpose of determining trends and visitor needs.
Service Providers. We may use third party service providers to perform certain services on our behalf on the Online Resources, such as hosting the Online Resources, measuring activities on the Online Resources and analytics, and performing other administrative services. We may provide these service providers access to information to carry out the services they are providing.
Analytics. We use Google Analytics to help us understand how visitors use our Online Resources, so that we may improve our services. Information about how Google Analytics uses data, and how you may control what information is shared with Google, can be found here.
We also may access, use, preserve, transfer and disclose your information to third parties: (i) to satisfy any applicable law, regulation, subpoenas, governmental requests or legal process if in our good faith opinion such is required or permitted by law; (ii) to protect and/or defend the policies applicable to the Online Resources, including investigation of potential violations thereof; (iii) to protect the safety, rights, property or security of the Online Resources or any third party; and/or (iv) to detect, prevent or otherwise address fraud, security or technical issues.
We reserve the right to disclose and transfer all information: (a) to a subsequent owner, co-owner or operator of the Online Resources or applicable assets; or (b) in connection with a merger, consolidation, restructuring, the sale of substantially all of our interests and/or assets or other corporate change, including, during the course of any due diligence process.
We will retain your information only for as long as necessary to fulfill the purposes for which it was collected and processed, including for the purposes of satisfying any legal, regulatory, accounting or reporting requirements.
You are responsible for maintaining the accuracy of the information you submit to us. You may provide updates and changes by contacting us at the address below. If so, we will make good faith efforts to make requested changes in our then-active databases as soon as reasonably practicable.
We do not knowingly collect any information from children younger than the age of thirteen (13) as required by U.S. law. We will delete any information collected that we later determine to be from a user younger than the age of thirteen (13). If you are a parent or guardian of a child under the age of thirteen (13) and believe he or she has disclosed information to us, please contact us at the address below.
We reserve the right to change this Privacy Policy at any time. Any changes will be effective immediately upon the posting of the revised Privacy Policy. We encourage visitors to frequently check this Privacy Policy to stay informed about any changes to this Privacy Policy. The date at the bottom of this Privacy Policy will be updated for each revision.
You may direct any questions or concerns regarding the use or disclosure of your information, or any other matter related to this Privacy Policy to:
ADvantage Therapeutics Inc.
195 NW 40th Street
Miami, FL 33127